OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers and other diseases. Its pipeline centers on small-molecule drug candidates designed with structure-based drug design to selectively target mutated forms of biologically validated proteins, including PI3Kα.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaInvestigational small-molecule therapies being advanced through preclinical and clinical development.
Programs designed to selectively inhibit mutated PI3Kα drivers in cancer and related diseases.
Structure-based discovery capabilities using medicinal chemistry, x-ray crystallography, and computation.
Asiakkaat
OnKure does not sell commercial products today; its near-term counterparties are research sites, CROs, manufacturers, regulators, and potential development collaborators. If approved, its eventual customers would be physicians, patients, hospitals, and third-party payors in oncology and related specialty markets.
They support the development of OKI-219 and future programs by running studies and generating clinical data.
They review clinical, manufacturing, and safety data needed for marketing approval.
They provide drug substance, finished product, packaging, and scale-up support for development and launch.
They would use approved therapies for cancers and other diseases driven by specific mutations.
They determine coverage and reimbursement that would affect adoption of any approved product.
Strategia
OnKure’s strategy is to advance a focused pipeline of precision medicines built around mutated PI3Kα and related validated targets. The company is also building the clinical, manufacturing, intellectual property, and financing capabilities needed to move a drug candidate from discovery into approval and eventual commercialization.
The company is substantially dependent on this lead program for value creation.
A broader pipeline reduces single-asset dependence and expands long-term optionality.
Biopharma value depends on scalable supply, launch capability, and market access if approved.
Maantiede
OnKure is incorporated in Delaware and has its principal executive offices in Boulder, Colorado. Its business is primarily U.S.-based today, with future development, regulatory, and commercialization activities potentially extending internationally through patents, clinical operations, and market access.
Riskit
OnKure faces the typical risks of a clinical-stage biotech: no approved products, no product revenue, and heavy dependence on successful clinical and regulatory outcomes. Its concentration in a lead asset, the need for additional capital, and the uncertainty of reimbursement and market acceptance all create substantial execution risk.
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
Drug candidates can fail to demonstrate efficacy, safety, or tolerability in trials.
Kohdistuu: Clinical-stage pipeline
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
Approval depends on successful trial results, manufacturing readiness, and agency review.
Kohdistuu: FDA and other regulators
- Financing riskVaikutus: KorkeaTodennäköisyys: Korkea
The company expects to need additional capital to fund operations and development.
Kohdistuu - Lead-asset concentrationVaikutus: Korkea
The company is substantially dependent on OKI-219, so setbacks would materially harm the business.
Kohdistuu: OKI-219
- Commercialization and reimbursement riskVaikutus: KeskitasoTodennäköisyys: Matala
Even approved therapies may face coverage, pricing, and adoption barriers.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical trials, manufacturing, and discovery costs are expensed as incurred and drive period results.
Vaikutus: Major driver of operating loss
The company leases all facilities, so lease liabilities and right-of-use assets affect the balance sheet and expense timing.
Vaikutus: Occupancy and balance sheet presentation
Private placements and convertible debt may require valuation judgments and affect non-operating items.
Vaikutus: Financing gains/losses and dilution analysis
Employee and director equity awards can be a meaningful non-cash expense for a development-stage company.
Vaikutus: Operating expense and dilution
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
NextCure, Inc.
NXTC · Pharmaceutical Preparations
Prelude Therapeutics Inc
PRLD · Pharmaceutical Preparations
TuHURA Biosciences, Inc.
HURA · Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV is a Nevada-based clinical-stage immuno-oncology company focused on developing therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
Enliven Therapeutics, Inc.
ELVN · Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
NovoCure Ltd
NVCR · Surgical & Medical Instruments & Apparatus
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients.
Päivitetty: 24.9.2026